Skip to main content

Table 1 Univariate analysis for OS and PFS in GBM patients of TCGA database

From: Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients

Variable

No. (%)

Median OS (months)

P

Median PFS (months)

P

Age (years)

  

 < 0.001

 

0.007

 ≥ 60

152 (52.96)

11.28

 

5.82

 

 < 60

135 (47.04)

17.79

 

7.86

 

Gender

  

0.009

 

0.145

 Male

169 (58.89)

13.35

 

7.04

 

 Female

118 (41.11)

15.65

 

7.36

 

Ethnicity

  

0.954

 

0.686

 Hispanic or Latino

5 (2.21)

14.22

 

5.98

 

 Not Hispanic or Latino

221 (97.79)

14.01

 

7.04

 

LANCL2 gene status

  

0.023

 

0.123

 Amplification

157 (27.12)

13.78

 

6.67

 

 No alteration

422 (72.88)

14.50

 

7.20

 

EGFR gene status

  

0.042

 

0.230

 Amplification

252 (43.52)

14.01

 

6.84

 

 No alteration

327 (56.48)

14.50

 

7.66

 

LANCL2 and EGFR genes status

  

0.013

 

0.509

 Co-amplification

156 (26.94)

13.78

 

6.67

 

 No alteration

423 (73.06)

14.53

 

7.30

 

LANCL2 mRNA status

  

0.224

 

0.664

 Overexpression

56 (36.36)

13.78

 

7.04

 

 No alteration

98 (63.64)

13.61

 

5.98

 

EGFR mRNA status

  

0.778

 

0.136

 Overexpression

75 (48.70)

14.93

 

6.41

 

 No alteration

79 (51.30)

12.95

 

6.90

 

LANCL2 and EGFR mRNA status

  

0.930

 

0.689

 Concurrent overexpression

42 (27.27)

15.39

 

6.41

 

 No alteration

112 (72.73)

13.12

 

6.84

Â